Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Diamedica Therapeutics Inc's Business Segments
Diamedica Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Single Reportable Segment
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Single Reportable Segment0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Single Reportable Segment0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | - | - |
Description of Diamedica Therapeutics Inc
Diamedica Therapeutics Inc. is a biotechnology company that specializes in developing innovative treatments for neurological and kidney diseases. The company was founded in 2007 and is headquartered in Minneapolis, Minnesota.
One of the primary focuses of Diamedica Therapeutics is on developing therapies to treat ischemic stroke, a condition caused by the blockage of blood flow to the brain. Ischemic stroke is a leading cause of disability and death worldwide, and there is currently a significant unmet need for effective treatments. Diamedica aims to provide novel treatments that can improve patients' outcomes and quality of life.
The company's main product candidate is DM199, a formulation of recombinant human tissue kallikrein-1 (KLK1). KLK1 is a naturally occurring protein in the human body that plays a critical role in regulating blood flow, inflammation, and tissue repair. DM199 is designed to enhance the body's natural healing processes and restore proper blood flow in patients with ischemic stroke.
Diamedica has conducted several clinical trials to assess the safety and efficacy of DM199. These trials have shown promising results, with DM199 demonstrating the potential to reduce brain damage caused by ischemic stroke and improve functional outcomes in patients.
In addition to ischemic stroke, Diamedica is also exploring the therapeutic potential of DM199 in other neurological conditions, such as acute neurodegenerative disorders and traumatic brain injury. The company believes that DM199's multifunctional properties make it a promising candidate for the treatment of various diseases where inflammation, blood flow regulation, and neuroprotection are critical factors.
Furthermore, Diamedica Therapeutics is also developing DM199 for the treatment of patients with acute kidney injury (AKI), a condition characterized by sudden damage to the kidneys. AKI can be caused by various factors, including medication toxicity, infections, and reduced blood flow to the kidneys. By leveraging the anti-inflammatory and tissue repair properties of DM199, Diamedica aims to develop a therapy that can mitigate kidney damage and improve patients' renal function.
To support its research and development efforts, Diamedica Therapeutics has established collaborations with leading academic institutions, research organizations, and pharmaceutical companies. These partnerships enable the company to access scientific expertise, resources, and funding necessary to advance its product development pipeline.
In summary, Diamedica Therapeutics Inc. is a biotechnology company focused on developing innovative treatments for neurological and kidney diseases. With its lead product candidate DM199, the company aims to address the unmet medical needs in ischemic stroke and acute kidney injury, offering potential therapeutic solutions to improve patients' clinical outcomes and quality of life.
One of the primary focuses of Diamedica Therapeutics is on developing therapies to treat ischemic stroke, a condition caused by the blockage of blood flow to the brain. Ischemic stroke is a leading cause of disability and death worldwide, and there is currently a significant unmet need for effective treatments. Diamedica aims to provide novel treatments that can improve patients' outcomes and quality of life.
The company's main product candidate is DM199, a formulation of recombinant human tissue kallikrein-1 (KLK1). KLK1 is a naturally occurring protein in the human body that plays a critical role in regulating blood flow, inflammation, and tissue repair. DM199 is designed to enhance the body's natural healing processes and restore proper blood flow in patients with ischemic stroke.
Diamedica has conducted several clinical trials to assess the safety and efficacy of DM199. These trials have shown promising results, with DM199 demonstrating the potential to reduce brain damage caused by ischemic stroke and improve functional outcomes in patients.
In addition to ischemic stroke, Diamedica is also exploring the therapeutic potential of DM199 in other neurological conditions, such as acute neurodegenerative disorders and traumatic brain injury. The company believes that DM199's multifunctional properties make it a promising candidate for the treatment of various diseases where inflammation, blood flow regulation, and neuroprotection are critical factors.
Furthermore, Diamedica Therapeutics is also developing DM199 for the treatment of patients with acute kidney injury (AKI), a condition characterized by sudden damage to the kidneys. AKI can be caused by various factors, including medication toxicity, infections, and reduced blood flow to the kidneys. By leveraging the anti-inflammatory and tissue repair properties of DM199, Diamedica aims to develop a therapy that can mitigate kidney damage and improve patients' renal function.
To support its research and development efforts, Diamedica Therapeutics has established collaborations with leading academic institutions, research organizations, and pharmaceutical companies. These partnerships enable the company to access scientific expertise, resources, and funding necessary to advance its product development pipeline.
In summary, Diamedica Therapeutics Inc. is a biotechnology company focused on developing innovative treatments for neurological and kidney diseases. With its lead product candidate DM199, the company aims to address the unmet medical needs in ischemic stroke and acute kidney injury, offering potential therapeutic solutions to improve patients' clinical outcomes and quality of life.
Diamedica Therapeutics Inc is a biotechnology company focused on the development and commercialization of innovative therapies for serious diseases, particularly those related to diabetes and neurological complications. Here is an extensive overview of the segments, products, and services that the company offers:
Segments
1. Therapeutics
- Neurological Disorders: This segment encompasses products aimed at treating complications arising from neurological conditions. The focus may include therapies for conditions like diabetic neuropathy, which are prevalent in diabetes patients and lead to significant morbidity.
- Metabolic Disorders: Targeting metabolic complications associated with diabetes, products in this segment are designed to address both acute and chronic symptoms as well as the underlying pathophysiology of diabetes-related disorders.
2. Research and Development (R&D)
- Investment in R&D is critical for Diamedica, particularly in the early stages of drug development. This segment includes clinical trials, preclinical studies, and exploration of new therapeutic targets.
3. Clinical Programs
- This involves the execution of clinical trials to evaluate the efficacy and safety of their drug candidates. The focus may be on both Phase I, Phase II, and Phase III trials, depending on where the drugs stand in the development pipeline.
Products
1. Lead Drug Candidates
- DM-199: This is a recombinant form of human treatment for kidney and metabolic disorders connected to diabetes. The drug candidate may focus on restoring regulatory functions that are disrupted in diabetic patients to mitigate complications.
- Other Therapeutics: While DM-199 is a primary focus, Diamedica may have additional candidates in various stages of development targeting specific diabetic complications or neurological disorders.
2. Pipeline Products
- Diamedica aims to develop a diverse pipeline that includes various compounds aimed at treating different manifestations of diabetes and related diseases. This can include both small molecules and biologics.
Services
1. Clinical Trial Services
- Diamedica often collaborates with clinical research organizations (CROs) to conduct clinical trials, ensuring compliance with regulatory standards and effective management of trial operations.
2. Regulatory Support
- The company may provide regulatory consulting and support services to facilitate the submission of Investigational New Drug (IND) applications, New Drug Applications (NDAs), and other regulatory documents to health authorities.
3. Partnerships and Collaborations
- Establishing strategic partnerships with other biotech firms, academic institutions, and healthcare organizations can leverage shared resources for drug development and clinical testing.
4. Patient Engagement Initiatives
- Diamedica may engage with patient advocacy groups and conduct outreach programs to better understand the needs of patients and caregivers, which can inform product development and clinical trial design.
Research Focus Areas
1. Diabetes-Related Complications: Exploring interventions that could improve outcomes for patients experiencing complications related to diabetes, including cardiovascular diseases, renal issues, and neuropathies.
2. Regenerative Medicine: Investigating therapeutic approaches that may serve to regenerate tissues and improve organ function impaired by chronic diseases, including diabetes.
3. Novel Therapeutic Targets: Utilizing advanced technologies like genomics and proteomics to identify new targets for drug development in the metabolic and neurological realms.
Conclusion
Diamedica Therapeutics Inc is dedicated to tackling significant health issues, primarily focusing on innovative treatments for diabetes and its related complications. Through a combination of therapeutic innovation, robust research and development initiatives, and a commitment to patient engagement, the company is positioned to make a substantial impact in the biopharmaceutical sector. Their ongoing clinical programs and pipeline development reflect the strategic commitment to addressing unmet medical needs in the realm of metabolic and neurological diseases.
Segments
1. Therapeutics
- Neurological Disorders: This segment encompasses products aimed at treating complications arising from neurological conditions. The focus may include therapies for conditions like diabetic neuropathy, which are prevalent in diabetes patients and lead to significant morbidity.
- Metabolic Disorders: Targeting metabolic complications associated with diabetes, products in this segment are designed to address both acute and chronic symptoms as well as the underlying pathophysiology of diabetes-related disorders.
2. Research and Development (R&D)
- Investment in R&D is critical for Diamedica, particularly in the early stages of drug development. This segment includes clinical trials, preclinical studies, and exploration of new therapeutic targets.
3. Clinical Programs
- This involves the execution of clinical trials to evaluate the efficacy and safety of their drug candidates. The focus may be on both Phase I, Phase II, and Phase III trials, depending on where the drugs stand in the development pipeline.
Products
1. Lead Drug Candidates
- DM-199: This is a recombinant form of human treatment for kidney and metabolic disorders connected to diabetes. The drug candidate may focus on restoring regulatory functions that are disrupted in diabetic patients to mitigate complications.
- Other Therapeutics: While DM-199 is a primary focus, Diamedica may have additional candidates in various stages of development targeting specific diabetic complications or neurological disorders.
2. Pipeline Products
- Diamedica aims to develop a diverse pipeline that includes various compounds aimed at treating different manifestations of diabetes and related diseases. This can include both small molecules and biologics.
Services
1. Clinical Trial Services
- Diamedica often collaborates with clinical research organizations (CROs) to conduct clinical trials, ensuring compliance with regulatory standards and effective management of trial operations.
2. Regulatory Support
- The company may provide regulatory consulting and support services to facilitate the submission of Investigational New Drug (IND) applications, New Drug Applications (NDAs), and other regulatory documents to health authorities.
3. Partnerships and Collaborations
- Establishing strategic partnerships with other biotech firms, academic institutions, and healthcare organizations can leverage shared resources for drug development and clinical testing.
4. Patient Engagement Initiatives
- Diamedica may engage with patient advocacy groups and conduct outreach programs to better understand the needs of patients and caregivers, which can inform product development and clinical trial design.
Research Focus Areas
1. Diabetes-Related Complications: Exploring interventions that could improve outcomes for patients experiencing complications related to diabetes, including cardiovascular diseases, renal issues, and neuropathies.
2. Regenerative Medicine: Investigating therapeutic approaches that may serve to regenerate tissues and improve organ function impaired by chronic diseases, including diabetes.
3. Novel Therapeutic Targets: Utilizing advanced technologies like genomics and proteomics to identify new targets for drug development in the metabolic and neurological realms.
Conclusion
Diamedica Therapeutics Inc is dedicated to tackling significant health issues, primarily focusing on innovative treatments for diabetes and its related complications. Through a combination of therapeutic innovation, robust research and development initiatives, and a commitment to patient engagement, the company is positioned to make a substantial impact in the biopharmaceutical sector. Their ongoing clinical programs and pipeline development reflect the strategic commitment to addressing unmet medical needs in the realm of metabolic and neurological diseases.